196 related articles for article (PubMed ID: 38067406)
1. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Di Costanzo F; Napolitano F; Salomone F; Amato AR; Alberico G; Migliaccio F; Pecoraro G; Marra A; Crocetto F; Ruffo A; Scagliarini S; Rossetti S; Puglia L; Di Napoli M; Bianco R; Servetto A; Formisano L
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067406
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.
Turner L; Shamseer L; Altman DG; Weeks L; Peters J; Kober T; Dias S; Schulz KF; Plint AC; Moher D
Cochrane Database Syst Rev; 2012 Nov; 11(11):MR000030. PubMed ID: 23152285
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review.
Patel K; Ivanov A; Jocelyn T; Hantel A; Garcia JS; Abel GA
JAMA Netw Open; 2024 Jun; 7(6):e2414425. PubMed ID: 38829615
[TBL] [Abstract][Full Text] [Related]
5. Reporting Quality of Randomized Controlled Trials of Periodontal Diseases in Journal Abstracts-A Cross-sectional Survey and Bibliometric Analysis.
Kumar S; Mohammad H; Vora H; Kar K
J Evid Based Dent Pract; 2018 Jun; 18(2):130-141.e22. PubMed ID: 29747793
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC.
Salomone F; Di Costanzo F; Pecoraro G; Viscardi G; Viggiano A; Napolitano F; Santaniello A; Formisano L; Bianco R; Servetto A
Lung Cancer; 2022 Dec; 174():36-44. PubMed ID: 36302311
[TBL] [Abstract][Full Text] [Related]
7. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
Saleh RR; Meti N; Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
Cancer Med; 2020 Nov; 9(21):7888-7895. PubMed ID: 32886422
[TBL] [Abstract][Full Text] [Related]
8. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G).
Smith AB; Cocks K; Parry D; Taylor M
Qual Life Res; 2014 Apr; 23(3):971-6. PubMed ID: 24097080
[TBL] [Abstract][Full Text] [Related]
9. Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials.
Liang F; Guo X; Zhang S; Xue H; Chen Q; Hu X
Oncotarget; 2017 Nov; 8(57):97648-97656. PubMed ID: 29228640
[TBL] [Abstract][Full Text] [Related]
10. Reporting quality of randomised controlled trial abstracts among high-impact general medical journals: a review and analysis.
Hays M; Andrews M; Wilson R; Callender D; O'Malley PG; Douglas K
BMJ Open; 2016 Jul; 6(7):e011082. PubMed ID: 27470506
[TBL] [Abstract][Full Text] [Related]
11. Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Servetto A; Salomone F; Di Costanzo F; Iuliano R; Marandino L; Napolitano F; Santaniello A; De Placido P; De Placido S; Di Maio M; Formisano L; Bianco R
Crit Rev Oncol Hematol; 2022 Apr; 172():103649. PubMed ID: 35259486
[TBL] [Abstract][Full Text] [Related]
12. Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.
Karim F; Amin A; Liu M; Vishnuvardhan N; Amin S; Shabbir R; Swed B; Khan U
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627127
[TBL] [Abstract][Full Text] [Related]
13. Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology.
Xu C; Zhang S; Zhu GL; Yang KB; Zhang Y; Mao YP; Tang LL; Liu Q; Huang Y; Ma J
Int Rev Immunol; 2023; 42(2):91-100. PubMed ID: 35712868
[TBL] [Abstract][Full Text] [Related]
14. Systematic screening and assessment of psychosocial well-being and care needs of people with cancer.
Schouten B; Avau B; Bekkering GTE; Vankrunkelsven P; Mebis J; Hellings J; Van Hecke A
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012387. PubMed ID: 30909317
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
[TBL] [Abstract][Full Text] [Related]
16. Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.
Ter Veer E; van Kleef JJ; Sprangers MAG; Haj Mohammad N; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2018 Mar; 21(2):183-195. PubMed ID: 29380191
[TBL] [Abstract][Full Text] [Related]
17. Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes.
Servetto A; Di Maio M; Salomone F; Napolitano F; Paratore C; Di Costanzo F; Viscardi G; Santaniello A; Formisano L; Bianco R
BMC Med; 2023 Jul; 21(1):234. PubMed ID: 37400832
[TBL] [Abstract][Full Text] [Related]
18. Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis.
Catalá-López F; Aleixandre-Benavent R; Caulley L; Hutton B; Tabarés-Seisdedos R; Moher D; Alonso-Arroyo A
Trials; 2020 Jan; 21(1):34. PubMed ID: 31910857
[TBL] [Abstract][Full Text] [Related]
19. Defining the publication source of high-quality evidence in urology: an analysis of EvidenceUpdates.
Narayan VM; Chrouser K; Haynes RB; Parrish R; Dahm P
BJU Int; 2016 Jun; 117(6):861-6. PubMed ID: 26663761
[TBL] [Abstract][Full Text] [Related]
20. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials.
Adamowicz K
Qual Life Res; 2017 Apr; 26(4):813-822. PubMed ID: 27738867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
